Regulatory Approval - FDA approves daily pill version of weight-loss drug Wegovy, providing a new option for patients taking GLP-1 medication [1] Pharmaceutical Industry - The approval introduces a new formulation for a GLP-1 medication, potentially impacting the weight-loss drug market [1]

US stock futures dipped slightly on Tuesday after new data showed surprisingly strong growth in the US economy over the summer, leading investors to trim bets on near-term cuts from the Federal Reserve. S&P 500 (ES=F), Nasdaq 100 (NQ=F), and Dow Jones Industrial Average (YM=F) futures all fell around 0.2%, following the third win in a row for US stocks to start the week. Gold (GC=F) and silver (SI=F) also continued to pick up steam, adding onto a stunning rally that has the precious metals on pace for the ...

US stocks wobbled on Tuesday after fresh data showed surprisingly strong growth in the US economy over the summer, leading investors to trim bets on near-term interest-rate cuts. The S&P 500 (^GSPC) and tech-heavy Nasdaq Composite (^IXIC) both sat just above the flatline, while the blue-chip benchmark Dow Jones Industrial Average (^DJI) hovered just below. Overall, the major US gauges flipped between small gains and losses after scoring their third win in a row to start the week. Gold (GC=F) and silver ( ...

US stock futures held steady on Tuesday ahead of a flurry of delayed data releases that could fill in gaps in Wall Street's picture of the economy, but are seen as unlikely to change the landscape for rate-cut bets. S&P 500 (ES=F), Nasdaq 100 (NQ=F), and Dow Jones Industrial Average (YM=F) futures all hugged the flatline, following the third win in a row for US stocks to start the week. Gold (GC=F) and silver (SI=F) also continued to gain steam, adding on to a stunning rally that has the precious metals o ...

US stocks were mixed at the start of the trading session on Tuesday after new data showed surprisingly strong growth in the US economy over the summer, leading investors to trim bets on near-term cuts from the Federal Reserve. The S&P 500 (^GSPC) and tech-heavy Nasdaq Composite (^IXIC) ticked upward to sit just above flat, by 0.07% and 0.1%, respectively, following the third win in a row for US stocks to start the week. The blue chip-heavy Dow Jones Industrial Average (^DJI), meanwhile, shed roughly 0.06% ...

US stock futures dipped slightly on Tuesday after new data showed surprisingly strong growth in the US economy over the summer. S&P 500 (ES=F), Nasdaq 100 (NQ=F), and Dow Jones Industrial Average (YM=F) futures all fell around 0.2%, following the third win in a row for US stocks to start the week. Gold (GC=F) and silver (SI=F) also continued to pick up steam, adding onto a stunning rally that has the precious metals on pace for their best year in more than four decades. The recent string of gains on Wal ...

US stocks tipped higher on Tuesday after fresh data showed surprisingly strong growth in the US economy over the summer, leading investors to trim bets on near-term interest-rate cuts. The S&P 500 (^GSPC) and tech-heavy Nasdaq Composite (^IXIC) both rose around 0.4%, with the benchmark index vying for a fresh record close. The blue-chip benchmark Dow Jones Industrial Average (^DJI) gained around 0.2%. The turn higher came after the major gauges on Monday notched their third win in a row. Gold (GC=F) and ...

Group 1 - The U.S. FDA has approved the first-ever GLP-1 pill for obesity from Novo Nordisk, which could increase treatment access for more patients [1] - This approval positions Novo Nordisk ahead of its main competitor, Eli Lilly, in the obesity treatment market, which is projected to be worth around $100 billion by the 2030s [2] - Analysts believe that oral pills could capture a 24% market share, equating to approximately $22 billion, in the global weight loss drug market by 2030 [3] Group 2 - Novo Nordisk's executive vice president emphasized that having an oral option will motivate different patient segments to seek treatment, enhancing access and ease of use compared to injections [4]

Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly https://t.co/7qqZt3bFXY ...

Core Viewpoint - Novo Nordisk plans to launch a new pill in the U.S. market shortly after the new year, with a cash price set at $149 per month for the initial dosage [1] Company Summary - The new pill will be available for purchase in the U.S. soon after the start of the new year [1] - The pricing strategy includes a cash price of $149 per month for the starting dose [1]